Harrow Health, Inc.
NASDAQ:HROWDrug Manufacturers - Specialty & Generic
+$0.12 today
- Market cap
- $1.21B
- Beta
- 0.28
- P/E (TTM)
- -104.7
- EPS (TTM)
- -$0.40
Volume 0.87M
Average 0.75M
HROW Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Harrow Health, Inc.NASDAQ: HROW
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow growth accelerates
Q1 FY2026 financing cash flow of $48.91M rose 212560.9% year over year, ahead of the +23.2% change in trailing-twelve-month financing cash flow.
Context
- Financing cash flow amounted to 4.7% of revenue in FY2025, down 9.6 pp from a year earlier.
- Financing cash flow increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +212560.9% holds above the trailing-twelve-month pace of +23.2%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (12.72M) USD
- Year-over-year change
- -144.6%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (12.72M) | -144.6% |
| FY2024 | 2024-12-31 | 28.53M | -77.5% |
| FY2023 | 2023-12-31 | 126.53M | +133.7% |
| FY2022 | 2022-12-31 | 54.14M | +5.2% |
| FY2021 | 2021-12-31 | 51.47M | — |
Financing Cash Flow vs competitors
How HROW compares with its peers on the latest reported figures
- Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +23.2% is the 4th highest of 8, against a peer median of +5.5%.
- Financing cash flow amounts to 13.5% of revenue for HROW, versus a peer median of 1665.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $557.83M USD | +3601.6% | +628.3% | 1072.0% | |
| LTM Sep 2026 | $187.21M USD | +12713.7% | +354.8% | — | |
| LTM Mar 2026 | $171.98M USD | +5.5% | — | 2258.5% | |
| LTM Sep 2026 | $134.63M USD | -6.5% | +15.1% | 19.7% | |
| LTM Jun 2026 | $116.25M USD | -52.9% | +40.6% | 2.2% | |
| LTM Mar 2026 | CHF 105.86M CHF | -32.9% | +370.6% | 21003.4% | |
| LTM Mar 2026 | $47.24M USD | +93.8% | -8.9% | 14179.4% | |
| LTM Mar 2026 | $36.17M USD | +23.2% | — | 13.5% | |
TTRXTurn Therapeutics Inc. | LTM Mar 2026 | $13.71M USD | — | — | — |
| Peer median (excluding HROW) | — | +5.5% | +197.7% | 1665.2% | |
Competitors are the stored peer set for HROW. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (18.01M) | (14.09M) | (24.41M) | (17.48M) | (5.14M) |
| Depreciation & Amortization | 2.4M | 3.67M | 12.34M | 14.54M | 19.68M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 5.75M | 7.97M | 15.7M | 17.62M | 12.5M |
| Change in Working Capital | (253K) | (5.57M) | (7.14M) | (44.63M) | 185K |
| Accounts Receivables | (1.83M) | (1.86M) | (30.34M) | (80.23M) | 5.01M |
| Inventory | (255K) | (2.32M) | (4.33M) | 165K | (2.82M) |
| Accounts Payables | 1.73M | 933K | 31.8M | 37.5M | (4.61M) |
| Other Working Capital | 103K | (2.32M) | (4.26M) | (2.06M) | 2.6M |
| Other Non-Cash Items | 15.2M | 9.72M | 7.35M | 7.75M | 16.64M |
| Operating Cash Flow | 5.08M | 1.71M | 3.84M | (22.2M) | 43.86M |
| Capital Expenditures | (28.51M) | (7.77M) | (152.55M) | (38.67M) | (1.1M) |
| Acquisitions (Net) | 9.83M | 0 | 0 | 0 | (4.36M) |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 9.83M | 0 | 0 | 5.51M | 0 |
| Other Investing Activities | (36.55M) | 854K | (151.09M) | (37.08M) | (215K) |
| Investing Cash Flow | (18.69M) | (1.74M) | (152.55M) | (33.16M) | (5.46M) |
| Debt Repayment | 71.07M | 31.72M | 74.64M | 29.78M | 11.84M |
| Common Stock Issued | 0 | 22.66M | 64.52M | 0 | 467K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | (127K) | 0 | 0 | 0 | 0 |
| Other Financing Activities | (19.12M) | (234K) | (12.63M) | (1.25M) | (25.04M) |
| Financing Cash Flow | 51.47M | 54.14M | 126.53M | 28.53M | (12.72M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 37.87M | 54.1M | (22.19M) | (26.84M) | 25.68M |
| Free Cash Flow | (23.43M) | (6.07M) | (148.71M) | (60.88M) | 42.76M |
Harrow Health, Inc.
NASDAQ:HROW
Intrinsic Alpha fair value
Locked
Current Price
$32.16
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.